资源描述：
《重组人血管内皮抑素联合顺铂治疗恶性腹腔积液的临床观察》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。
1、重组人血管内皮抑素联合顺铀治疗恶性腹腔积液的临床观察肖锋肖茂良（通讯作者）唐友斌颜学军（湖南屮医药高等专科学校附属第一医院肿瘤一科412000）A的：评价重组人血管内皮抑素（恩度）联合顺铂腹腔注射治疗恶性腹腔积液的疗效与安全性。方法：76例经病理确诊的晚期恶性肿瘤合并腹腔积液患者，行腹腔穿刺引流后，随机分为两组。试验组：腹腔注射重组人血管内皮抑素60毫克，顺铂40毫克Dl,4,7,三次为1周期；对照组：单用顺铂40毫克腹腔注射D1,4,7,其余同试验组。按照WHO胸腹水疗效评价标准和NCI-CTCAE4
2、.0标准分别评估疗效及毒副反应。结果：试验组和对照组的客观有效率分别是65.7%和41.4%,，差异有统计学意义（p<0.05）;疾病控制率分别是94.2%和58.5%,差异有统计学意义（p<0.05）。试验组与对照组相比生活质量有改善的趋势。不良反应主要是白细胞减少，血小板K降，心脏毒性，恶心呕吐，两组无统计学差异（p>0.05＞。结论：重组人血管内皮抑素（恩度）联合顺铂腹腔注射治疗恶性腹腔积液疗效好，毒副反应小，值得临床推广。【关键词】重组人血管内皮抑素顺铂恶性腹腔积液R45A16
3、72-5085（2014）15-0043-02Clinicalresearchonrhendostatincombinedwithcis-platinumonpatientswithmaliganantperitonealeffusionXIAOFengXIAOMao-LiangTANGYou-Bin,YANXue-Jun（No.lOncologyDepartmentTheFirstAffiliatedHospitalofHunanCollegeforTCMZhuzhou,412000,China）【A
4、BSTRACT】OBJECTIVE:Toobservetheclinicalefficacyofrecombinanthumanendostaincombinedwithcis-platinuminthetreatmentofpatientswithmaliganantperitonealeffusion.METHODS:76patinetswithmaliganantperitonealeffusion,whowerediagnosedbypathology,wererandomlydividedin
5、totwogroupsafterabdominocentesis.Trialgroupweretreatedwithendostain60mgandcis-platinum40mgeachtimeondl,d4,d7；controlgroupweretreatedwithmonotherapyofcis-platinum40mgwiththesameprocedure..TheefficacywasevaluatedaccordingtoWHOcriteriaandsafetyaccordingtoNC
6、ICTCAE4.0versioncriteria..RESULTSTheobjectiveresponseratewas65.7%fortrialgroupand41.4%forcontrolgroup,thedifferencewasstasticalsignificance(p<0.05).Thediseasecontrolratewas94.2%fortrialgroupand58.5%forcontrolgroup,thedifferencewasstasticalsignificance
7、(p<0.05).Trialgroupshowedatendencytoimprovethequalityoflifecomparedtocontrolgroup..Toxicitiesmainlyincludedneutropenia、thrombocytopenia、Cardiactoxicityandnausea/vomiting，butthedifferencewasnotsignificant(p>0.05).CONCLUSION:Recombinanthunanendostati
8、ncombinedwithcis-platinumisaneffectiveandsafetytherapyformalignantperitonealeffusion,withfewertoxicreaction,whichiswothyofspreadingintheclinic.【keywords】：rh-endostatincis-platinummaliganantperitonealeffusion恶性腹腔积液是多种晚期恶性肿瘤
